ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

Despite the initial benefits of treating HER2-amplified breast cancer patients with the tyrosine kinase inhibitor lapatinib, resistance inevitably develops. Here we report that lapatinib induces the degradation of the nuclear receptor ERRα, a master regulator of cellular metabolism, and that the expression of ERRα is restored in lapatinib-resistant breast cancer cells through reactivation of mTOR signalling. Re-expression of ERRα in resistant cells triggers metabolic adaptations favouring mitochondrial energy metabolism through increased glutamine metabolism, as well as ROS detoxification required for cell survival under therapeutic stress conditions. An ERRα inverse agonist counteracts these metabolic adaptations and overcomes lapatinib resistance in a HER2-induced mammary tumour mouse model. This work reveals a molecular mechanism by which ERRα-induced metabolic reprogramming promotes survival of lapatinib-resistant cancer cells and demonstrates the potential of ERRα inhibition as an effective adjuvant therapy in poor outcome HER2-positive breast cancer.

[1]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[2]  J. Mackey,et al.  Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. , 2009, Cancer research.

[3]  V. Giguère,et al.  A Polymorphic Autoregulatory Hormone Response Element in the Human Estrogen-related Receptor α (ERRα) Promoter Dictates Peroxisome Proliferator-activated Receptor γ Coactivator-1α Control of ERRα Expression* , 2004, Journal of Biological Chemistry.

[4]  Tyler J Moss,et al.  The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells , 2012, Molecular systems biology.

[5]  Alex J Walsh,et al.  Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. , 2013, Cancer research.

[6]  T. Pawson,et al.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.

[7]  S. Chandarlapaty,et al.  Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor , 2010, Clinical Cancer Research.

[8]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[9]  V. Giguère,et al.  Loss of estrogen-related receptor α promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances , 2013, Proceedings of the National Academy of Sciences.

[10]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[11]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[12]  V. Giguère,et al.  Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. , 2010, Cancer research.

[13]  R. Landgraf,et al.  PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells , 2012, Breast Cancer Research and Treatment.

[14]  Brian J. Wilson,et al.  The homeobox protein Prox1 is a negative modulator of ERR{alpha}/PGC-1{alpha} bioenergetic functions. , 2010, Genes & development.

[15]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Cardiff,et al.  PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis* , 2009, The Journal of Biological Chemistry.

[17]  V. Giguère.  Transcriptional control of energy homeostasis by the estrogen-related receptors. , 2008, Endocrine reviews.

[18]  P. Jänne,et al.  Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers , 2008, Clinical Cancer Research.

[19]  R. Bianco,et al.  Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models , 2014, Breast Cancer Research.

[20]  R. Nahta,et al.  Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. , 2012, Anti-cancer agents in medicinal chemistry.

[21]  Violeta Serra,et al.  Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. , 2008, Cancer research.

[22]  J. Menéndez,et al.  The tyrosine kinase receptor HER2 (erbB‐2): From oncogenesis to adipogenesis , 2008, Journal of cellular biochemistry.

[23]  J. Engelman,et al.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. , 2014, Cancer cell.

[24]  W. Berger,et al.  The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells , 2011, Breast Cancer Research and Treatment.

[25]  V. Giguère,et al.  The PGC-1/ERR signaling axis in cancer , 2013, Oncogene.

[26]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[27]  Takashi Suzuki,et al.  Estrogen-Related Receptor α in Human Breast Carcinoma as a Potent Prognostic Factor , 2004, Cancer Research.

[28]  V. Giguère,et al.  Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond , 2012, Nature Reviews Cancer.

[29]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Hung,et al.  Signaling cross-talk in the resistance to HER family receptor targeted therapy , 2014, Oncogene.

[31]  Ulrik B. Nielsen,et al.  Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.

[32]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[33]  E. Ariazi,et al.  Estrogen-related Receptor α and Estrogen-related Receptor γ Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer , 2002 .

[34]  G. Bourque,et al.  Molecular and genetic crosstalks between mTOR and ERRα are key determinants of rapamycin-induced nonalcoholic fatty liver. , 2013, Cell metabolism.

[35]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Hazle,et al.  The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis , 2012, Cell.

[37]  V. Giguère,et al.  Epidermal Growth Factor–Induced Signaling in Breast Cancer Cells Results in Selective Target Gene Activation by Orphan Nuclear Receptor Estrogen-Related Receptor α , 2005 .

[38]  V. Giguère,et al.  Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. , 2005, Molecular endocrinology.

[39]  J. Settleman,et al.  Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. , 2011, Cancer cell.

[40]  R. Evans,et al.  Identification of a new class of steroid hormone receptors , 1988, Nature.

[41]  Joerg M. Buescher,et al.  A roadmap for interpreting (13)C metabolite labeling patterns from cells. , 2015, Current opinion in biotechnology.

[42]  J. Engelman,et al.  Acquired resistance to tyrosine kinase inhibitors during cancer therapy. , 2008, Current opinion in genetics & development.

[43]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[44]  B. Faubert,et al.  PGC-1α supports glutamine metabolism in breast cancer , 2013, Cancer & Metabolism.

[45]  James S. Duncan,et al.  Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.

[46]  J. Settleman,et al.  Mechanisms of acquired resistance to targeted cancer therapies. , 2012, Future oncology.

[47]  R. Kalluri,et al.  Corrigendum: PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis , 2014, Nature Cell Biology.

[48]  P. Puigserver,et al.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.

[49]  S. Hilsenbeck,et al.  β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib , 2011, Breast Cancer Research.

[50]  H. Askari,et al.  Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents. , 2011, Journal of medicinal chemistry.

[51]  S. Hilsenbeck,et al.  Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation , 2011, Breast Cancer Research.

[52]  Mourad Tighiouart,et al.  Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells , 2011, Molecular Cancer Therapeutics.

[53]  J. Heth,et al.  Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer , 2012, Journal of Clinical Neuroscience.

[54]  R. Kalluri,et al.  PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation to promote metastasis , 2014, Nature Cell Biology.

[55]  Jeff S. Jasper,et al.  The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. , 2011, Cancer cell.